News

Article

Scleral melts: Patching ultimately may prove to be unnecessary

Author(s):

Eye patching

Necrotizing scleritis can be treated medically; communication with patients is key.

This article was reviewed by Victor L. Perez, MD

Corneal and ocular inflammation is just the tip of the proverbial iceberg, according to Victor L. Perez, MD, who noted that he views those as indicative of deeper common problems, i.e., autoimmune or systemic disorders and infections.

Dr. Perez is Distinguished Professor of Ophthalmology, Stephen and Frances Foster Endowed Chairman, and director of the Foster Center for Ocular Immunology, Duke Eye Center University School of Medicine, Durham, NC.

Step-by-step protocol
Dr. Perez described the protocol he abides by when confronted with a patient with a scleral melt. 

First, in contrast to many physicians, Dr. Perez said he steps away from the slit-lamp and talks to the patient. 

“The clinical history is important,” he said. “I review the bodily systems and medications and perform an external examination, which is crucial for diagnosing all possible diseases that can be associated with the scleral melt.”

Dr. Perez also pointed out that a full ophthalmic examination should include everything. He noted that physicians should use their pattern recognition skills. 

“We are very good at evaluating the eye and recognizing presentations that can help us with the differential diagnosis,” he said.

Some of those possibilities are mild necrotizing scleritis, severe scleral melt, infectious scleritis, and scleromalacia, which is not an active form of scleritis that rarely needs patching.

Know your location
Dr. Perez then advises physicians to be aware of diseases that are common in their locations, because this knowledge will help establish a diagnosis.

He provided an example based on his Boston-based training where most of the etiologies of necrotizing scleritis, including 57%, that were associated with an autoimmune disease or connective-tissue disorder.

This included systemic vasculitis disease in 48%, infection disease in 7%, and rosacea, atopy, or foreign body, in 2%. 

A change of location to Bascom Palmer Eye Institute in Miami showed a different local profile, in which the most common presentation was infectious scleritis. In North Carolina, Dr. Perez said he sees several causes of necrotizing scleritis. 

To treat or not to treat
An illustrative case of a scleral melt caused by a disease is that of a 60-year-old woman who presented with eye pain associated with a scleral lesion. 

The patient had rheumatoid arthritis. This scenario, among others, may move physicians to the next step: to patch or not to patch. However, in Dr. Perez’s opinion, the more important consideration is to treat or not to treat.

To address that question, Dr. Perez cited two studies. Watson and Hayreh (Br J Ophthalmol 1976;60:163-91) reported that 29% of patients died within 5 years of the onset of necrotizing scleritis and 67% of those deaths resulted from extraocular vasculitis. Foster et al. (Ophthalmology 1984;10:1253-63) reported that 54% of patients who were not immunosuppressed died.

“Medical therapy, rather than surgery, is always the first line of therapy,” he said.

Dr. Perez cited a review of the expert guidelines for use of immunosuppressive drugs in patients with ocular inflammatory diseases (Am J Ophthalmol 2000;130:492-513). It looked at the patients who need immunosuppression. 

“Nearly any ocular inflammatory disorder requires chronic systemic steroids,” he said. “These diseases include Behcet’s disease, necrotizing scleritis and vasculitides, birdshot retinochoroidopathy, multifocal choroiditis and panuveitis, serpiginous choroidopathy, mucous membrane pemphigoid, and sympathetic ophthalmia. Necrotizing scleritis is one of the top candidates for immunosuppression.”

Dr. Perez advised physicians to avoid jumping immediately to patching. He said it is important to first show how severe the necrotizing scleritis is and look for an infectious necrotizing scleritis. 

“Do not panic,” he said. “ All scleral melts will look emergent, but surgical intervention may not be needed. Always culture the patient and biopsy if necessary.”
 

To patch or not to patch
When considering surgery, the inflammation or infection must first be controlled. The scleral tissue used can be patch graft or the entire sclera, the latter of which is preferable. 

To prepare a patch graft, Dr. Perez likes to use a template to draw the area of scleral necrosis and create a patch graft; healthy tissue must be present in order to suture the graft.

The patch graft should be covered with conjunctiva or a mucous membrane graft. The former is the better approach, but in some cases the conjunctiva may have disintegrated.

Infectious keratitis
When treating infectious keratitis/keratitis, the potential algorithm is culturing, topical and/or systemic antibiotics and early surgery, which includes cryotherapy with conjunctival resection and antibiotic irrigation and perhaps subpalpebral lavage with an antibiotic or an antifungal with a corneal scleral patch graft.

Victor L. Perez, MD
E: victor.perez.quinones@duke.edu
Dr. Perez has no financial interests in any aspects of this report.
 

Related Videos
AAO 2024: Matt Giegengack, MD: Injectable endothelial cell therapy shows promise for improving vision and reducing glare in corneal edema
EyeCon 2024: Adam Wenick, MD, talks about myopic interventions across the lifespan
Adam Wenick, MD, chairs EyeCon session: New treatments in geographic atrophy from detection to intervention
EyeCon 2024: Laura M. Periman, MD, shares her passion for dry eye disease, discussing her surprising discovery of the Alpenglow Sign in Demodex blepharitis
David Eichenbaum, MD, presents advances in AMD therapy, highlights different mechanisms with a common goal
Cochair Kelly K. Nichols, OD, PhD, MPH, FAAO, highlights her passion for dry eye research and the vital collaboration between ophthalmology and optometry
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
© 2024 MJH Life Sciences

All rights reserved.